Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Rochester, New York 14642


The purpose of this study is to find out how effectively cervix cancer is controlled when radiation is combined with low-dose chemotherapy (Taxotere) . The use of low-dose Taxotere, once per week, with radiation is a new treatment for cervical cancer. This study will also see how well this treatment regimen can be tolerated.


Inclusion Criteria: - Histologic confirmation of squamous, adenocarcinoma, or adenosquamous carcinoma of the uterine cervix including FIGO (International Federation of Gynecologists and Obstetricians) stage IB to IVA with or without pelvic adenopathy. - No evidence of para-aortic or distant metastases. Must have evaluable disease. - Zubrod Performance Status 0-2 or Karnofsky Performance Status > 60 - Laboratory values must be as follows: White blood cell count: > 3,000/mm3,Absolute granulocyte count: > 1,500/mm3, Hemoglobin > 8.0 g/dl, Platelets: > 100,000/mm3, Serum creatinine: < 2.5 mg/dl, Serum calcium: < 1.3 x institutional upper normal limit,Hepatic criteria as follows: Total Bilirubin < ULN for the institution, - Signed study-specific informed consent p - Age > 18 years. - Peripheral neuropathy must be < grade 1. Exclusion Criteria: - Prior or simultaneous malignancies (other than skin cancer) unless disease-free - Medical illness preventing the use of taxane-based chemotherapy. - Carcinoma of the cervix with the following histology: melanoma, sarcoma, small carcinoid, glassy cell, clear cell, and adenoid cystic. - Previous or current medical or psychiatric illness that would prevent informed consent - Patients known to be infected with HIV or a history of AIDS are excluded. - Prior surgery for carcinoma of the cervix other than a biopsy. - Patients with para-aortic disease. - Previous pelvic radiation therapy or systemic chemotherapy is not permitted. - Women who are pregnant or breast-feeding are excluded from this study. - Previous history of hypersensitivity reaction to Taxotere or other drugs formulated with polysorbate 80 must be excluded.

Study is Available At:

Original ID:

URCC 1328



Secondary ID:

Study Acronym:

Brief Title:

Low-Dose Taxotere® (Docetaxel) With Concurrent Radiotherapy For Localized, Inoperable Carcinoma Of The Uterine Cervix

Official Title:

A Phase Ii Clinical Study Using Weekly Low-Dose Taxotere® (Docetaxel) With Concurrent Radiotherapy For Localized, Inoperable Carcinoma Of The Uterine Cervix

Overall Status:


Study Phase:

Phase 2



Minimum Age:

18 Years

Maximum Age:


Quick Facts

Healthy Volunteers
Oversight Has DMC
Study Is FDA Regulated
Study Is Section 801
Has Expanded Access

Study Source:

University of Rochester

Oversight Authority:

United States: Institutional Review Board

Reasons Why Stopped:

Study Type:


Study Design:

Allocation: Non-Randomized, Endpoint Classificati

Number of Arms:


Number of Groups:


Total Enrollment:


Enrollment Type:

Overall Contact Information

Official Name:Yuhchyau Chen, MD, Ph.D
Principal Investigator
Universtiy of Rochester, Dept of Radiation Oncology

Study Dates

Start Date:January 2005
Primary Completion Date:June 2006
Primary Completion Type:Actual
Verification Date:May 2009
Last Changed Date:May 15, 2009
First Received Date:September 12, 2005

Study Outcomes

There are no available Study Outcomes

Study Interventions

Intervention Type:Drug
Intervention Type:Procedure
Name:Radiation Therapy

Study Arms

There are no available Study Arms

Study Agencies

Agency Class:Other
Agency Type:Lead Sponsor
Agency Name:University of Rochester

Sample and Retention Information

There are no available Sample and Retention Information

Study References

There are no available Study References

Data Source: ClinicalTrials.gov

Date Processed: November 18, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

This study is not currently recruiting Study Participants. The form below is not enabled.